Sunitinib efficacy and effects

Sunitinib (Sunitinib) is a prescription drug used to treat gastrointestinal stromal tumors whose cancer cannot be suppressed by taking imatinib mesylate

In all studies, the main measure of effectiveness is how long patients live without their tumors getting worse. Sunitinib was more effective than placebo in treating GIST and pancreatic neuroendocrine tumors. Patients with gastrointestinal stromal tumors who took sunitinib lived an average of 26.6 weeks without disease progression, compared with an average of 6.4 weeks for those who took a placebo. For pancreatic neuroendocrine tumors, the figure was 11.4 months in the sunitinib group and 5.5 months in the placebo group. In metastatic renal cell carcinoma, patients taking sunitinib lived an average of 47.3 weeks without disease progression, compared with an average of 22.0 weeks for patients receiving interferon alfa.

The original sunitinib drug has been launched in China and has entered the scope of Class B medical insurance. SpecificationsThe price of 12.5mg*28 tablets is around RMB 3,500. The original sunitinib drug has also been launched overseas. The price of 12.5mg*7 tablets is around RMB 1,500 (the price may fluctuate due to the exchange rate). There are also generic drugs produced in other countries. The price of 12.5mg*28 tablets produced by an Indian pharmaceutical factory is around RMB 750 (the price may fluctuate due to the exchange rate). The ingredients of the generic drugs produced abroad are basically the same as those of the original drugs at home and abroad. There may be differences in the prices of different specifications of drugs.